MX2017015973A - Composiciones y metodos para mejorar la neurogenesis en animales. - Google Patents

Composiciones y metodos para mejorar la neurogenesis en animales.

Info

Publication number
MX2017015973A
MX2017015973A MX2017015973A MX2017015973A MX2017015973A MX 2017015973 A MX2017015973 A MX 2017015973A MX 2017015973 A MX2017015973 A MX 2017015973A MX 2017015973 A MX2017015973 A MX 2017015973A MX 2017015973 A MX2017015973 A MX 2017015973A
Authority
MX
Mexico
Prior art keywords
animal
neurogenesis
improve
cognitive
animals
Prior art date
Application number
MX2017015973A
Other languages
English (en)
Other versions
MX379147B (es
Inventor
Pan Yuanlong
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56296871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017015973(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2017015973A publication Critical patent/MX2017015973A/es
Publication of MX379147B publication Critical patent/MX379147B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/142Amino acids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/158Fatty acids; Fats; Products containing oils or fats
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/174Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51Thiamines, e.g. vitamin B1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • A61K31/714Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Birds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fodder In General (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona métodos para mejorar la neurogénesis en un animal. En una modalidad, un método para mejorar la neurogénesis en un animal puede comprender identificar un animal que padece disminución cognitiva, que está en riesgo de padecer un deterioro cognitivo, que se diagnostica con una enfermedad, trastorno, u otra afección que afecta sus habilidades cognitivas, o que está en riesgo de contraer una enfermedad, trastorno, u otra afección que afecta sus habilidades cognitivas, y administrar al animal una composición que comprende un ácido graso insaturado (UFA), un compuesto que libera óxido nítrico (NORC), una vitamina B y un antioxidante, en donde la composición se administra en una cantidad eficaz para mejorar la neurogénesis en el animal.
MX2017015973A 2015-06-22 2016-06-21 Composiciones y métodos para mejorar la neurogénesis en animales. MX379147B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562182922P 2015-06-22 2015-06-22
US201562205937P 2015-08-17 2015-08-17
PCT/IB2016/053689 WO2016207794A1 (en) 2015-06-22 2016-06-21 Compositions and methods for enhancing neurogenesis in animals

Publications (2)

Publication Number Publication Date
MX2017015973A true MX2017015973A (es) 2018-04-20
MX379147B MX379147B (es) 2025-03-11

Family

ID=56296871

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015973A MX379147B (es) 2015-06-22 2016-06-21 Composiciones y métodos para mejorar la neurogénesis en animales.

Country Status (11)

Country Link
US (1) US20160367509A1 (es)
EP (1) EP3310349B1 (es)
JP (1) JP6820868B2 (es)
CN (1) CN107708446A (es)
AU (1) AU2016281870B2 (es)
BR (1) BR112017025664A2 (es)
CA (1) CA2987033C (es)
ES (1) ES2860427T3 (es)
MX (1) MX379147B (es)
RU (1) RU2735834C2 (es)
WO (1) WO2016207794A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3310349B1 (en) 2015-06-22 2021-01-13 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals
MX385552B (es) * 2016-09-29 2025-03-18 Soc Des Produits Nestle S A Star Ácidos grasos omega 3, compuesto que libera no y vitamina b12 como neuroprotector en pacientes sin demencia.
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
BR112019017949A2 (pt) * 2017-04-11 2020-05-19 Nestle Sa níveis de ácidos graxos ômega-3 e vitamina d para identificar e atenuar o envelhecimento cognitivo em indivíduos
WO2018188771A1 (en) * 2017-04-11 2018-10-18 Nestec S.A. Omega-3 fatty acid and vitamin d levels to identify and attenuate cognitive aging in individuals
EP3388061A1 (en) * 2017-04-11 2018-10-17 Nestec S.A. Omega 3 fatty acids, no releasing compound, vitamin b12 and choline as neuroprotectant in patients with no dementia
GR20170100368A (el) * 2017-08-04 2019-04-22 Νικολετα Ανδρεα Τουμαζατου Μπισκοτα υπερτροφης ανθρωπων και σκυλων
MX2020001765A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de enfermedad hepatica.
CN112839643A (zh) 2018-06-20 2021-05-25 胺细拉健康公司 用于治疗肌肉中脂肪浸润的组合物及方法
MX2022006412A (es) * 2019-12-19 2022-08-02 Nestle Sa Composiciones y metodos para proporcionar un beneficio de salud a un animal en crecimiento.
FR3135876B3 (fr) * 2022-05-25 2024-05-24 Nestle Sa Compositions et procédés pour mélanges d’aliments déshydratés pour animaux de compagnie
CN116268228B (zh) * 2022-12-23 2024-06-18 广西中医药大学 一种海马配合饲料及其应用
CN121668278A (zh) * 2026-02-10 2026-03-17 哈尔滨工业大学 一种增强记忆力和提高认知功能的组合物和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233670B1 (en) 1999-06-14 2008-09-17 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US20060014773A1 (en) * 2001-04-19 2006-01-19 Mccleary Edward L Mental agility lozenge, edible strip, food or drink
JP2003261456A (ja) 2002-03-08 2003-09-16 Howaizu:Kk 脳の老化予防剤
DK1583541T3 (da) * 2002-11-20 2011-04-11 Neuronova Ab Forbindelser og fremgangsmåder til at øge neurogenese
US6951658B1 (en) 2003-07-08 2005-10-04 Pearson Research & Development Limited Emu-based compositions for mental well-being and method of use
JP5240757B2 (ja) * 2005-02-22 2013-07-17 持田製薬株式会社 神経再生促進剤
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20090197823A1 (en) 2006-05-09 2009-08-06 Braincells, Inc. Aliskiren modulation of neurogenesis
US20100292330A1 (en) * 2007-10-04 2010-11-18 Yuanlong Pan Compositions and methods for enhancing cognitive function
EP2224930B1 (en) 2008-01-04 2016-06-15 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
WO2012030208A1 (en) 2010-09-03 2012-03-08 N.V. Nutricia Method and preparation for the treatment or prevention of anxiety or neurogenesis
WO2012083034A1 (en) 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US9351978B2 (en) 2012-02-29 2016-05-31 Mead Johnson Nutrition Company Neurogenesis screening method and uses thereof
EP3310349B1 (en) 2015-06-22 2021-01-13 Société des Produits Nestlé S.A. Compositions and methods for enhancing neurogenesis in animals

Also Published As

Publication number Publication date
CN107708446A (zh) 2018-02-16
WO2016207794A1 (en) 2016-12-29
MX379147B (es) 2025-03-11
CA2987033A1 (en) 2016-12-29
RU2018101989A3 (es) 2019-12-06
AU2016281870A1 (en) 2017-11-23
ES2860427T3 (es) 2021-10-05
JP2018528160A (ja) 2018-09-27
US20160367509A1 (en) 2016-12-22
RU2735834C2 (ru) 2020-11-09
JP6820868B2 (ja) 2021-01-27
EP3310349B1 (en) 2021-01-13
EP3310349A1 (en) 2018-04-25
AU2016281870B2 (en) 2020-09-10
CA2987033C (en) 2023-11-28
RU2018101989A (ru) 2019-07-22
BR112017025664A2 (pt) 2018-08-07

Similar Documents

Publication Publication Date Title
MX2017015973A (es) Composiciones y metodos para mejorar la neurogenesis en animales.
CO2021009163A2 (es) Composiciones de agente de arni de proteína precursora de amiloide (app) y método de uso de las mismas
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
CL2017003005A1 (es) Métodos de diagnóstico para tratamiento con linfocitos t
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
MX2017000143A (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
MX375417B (es) Uso de ácido (r)-2-[3-[[n-(benzoxazol-2-il)-n-3-(4-metoxifenoxi)propil]aminometil]fenoxi]butírico o una sal, o solvato del mismo para el tratamiento de la esteatosis hepática no alcohólica, supresión de la deposición de grasa en el hígado, y en la reducción de células de kupffer en el hígado.
BR112017005693A2 (pt) método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica.
NI201800014A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
BR112015029240A2 (pt) composto, composição e método de evitar ou tratar inflamação associada com inflamassoma nrlp3 em um indivíduo
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
MX385747B (es) Composiciones y métodos para modular la microflora gastrointestinal en un canino.
ECSP14033371A (es) Composiciones farmacéuticas y tratamiento de mastitis
MX2016016139A (es) Inhibidor del sistema complemento de ornithodoros moubata para utilizarse en el tratamiento de enfermedades mediadas por el sistema complemento en pacientes con polimorfismo de c5.
MX2018006961A (es) Hidratacion para animales.
CL2019000018A1 (es) Formas sólidas de un estimulador de sgc.
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
NZ735777A (en) Methods and compositions to inhibit symptoms associated with veisalgia
UY36173A (es) Metodo de tratamiento de enfermedades relacionadas con el factor inducible por hipoxia
CL2019001746A1 (es) Amidas aromáticas de ácido carboxílico
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2019007361A (es) Composiciones para el cuidado bucal.
CL2017000118A1 (es) Métodos y composiciones para tratar desórdenes relacionados con el vih
AR112291A1 (es) Composición para su uso en la prevención y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncológico